Anti-cancer Drug Discovery and Development: Bcl-2 Family Small Molecule Inhibitors

Overview

Journal Commun Integr Biol

Specialty Biology

Date 2013 Jan 22

PMID 23336025

Citations 25

Authors

Qiang Liu

Hong-Gang Wang

Affiliations

Soon will be listed here.

Abstract

Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family anti-apoptotic proteins, as well as selective SMIs to differentially target the two arms. Of these SMIs, ABT-263 (navitoclax), AT-101 [(-)-gossypol], and obatoclax (GX15-070) are currently in clinical trials for multiple cancers. While pan-Bcl-2 inhibitors such as AT-101 and obatoclax can be more toxic for inhibiting all members of the anti-apoptotic Bcl-2 family of proteins, resistance can quickly develop for ABT-263, a selective Bcl-2 inhibitor. In this article, we discuss the current status of Bcl-2 family SMIs in preclinical and clinical development. As Mcl-1 upregulation is a major mechanism of ABT-263 resistance, Mcl-1-specific inhibitors are expected to be efficacious both in combination/sequential treatments and as a single agent against cancers resistant to ABT-263.

Citing Articles

Cancer pharmacoinformatics: Databases and analytical tools.

Kamble P, Nagar P, Bhakhar K, Garg P, Sobhia M, Naidu S Funct Integr Genomics. 2024; 24(5):166.

PMID: 39294509 DOI: 10.1007/s10142-024-01445-5.

The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.

Sasso J, Tenchov R, Bird R, Iyer K, Ralhan K, Rodriguez Y Bioconjug Chem. 2023; 34(11):1951-2000.

PMID: 37821099 PMC: 10655051. DOI: 10.1021/acs.bioconjchem.3c00374.

Label-free drug interaction screening via Raman microscopy.

Altangerel N, Neuman B, Hemmer P, Yakovlev V, Rajil N, Yi Z Proc Natl Acad Sci U S A. 2023; 120(30):e2218826120.

PMID: 37463207 PMC: 10372630. DOI: 10.1073/pnas.2218826120.

Spatial Transcriptomics Identifies Expression Signatures Specific to Lacrimal Gland Adenoid Cystic Carcinoma Cells.

Moeyersoms A, Gallo R, Zhang M, Stathias V, Maeng M, Owens D Cancers (Basel). 2023; 15(12).

PMID: 37370820 PMC: 10296284. DOI: 10.3390/cancers15123211.

Design, Synthesis, and Antiproliferative Activity of Benzopyran-4-One-Isoxazole Hybrid Compounds.

Gupta S, Park S, Mozaffari S, El-Aarag B, Parang K, Tiwari R Molecules. 2023; 28(10).

PMID: 37241960 PMC: 10224329. DOI: 10.3390/molecules28104220.

References

Parikh S, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K . Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010; 10(4):285-9. DOI: 10.3816/CLML.2010.n.059. View

Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C . Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem. 2011; 287(1):68-80. PMC: 3249122. DOI: 10.1074/jbc.M111.271205. View

McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, OHagan B . Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis. 2011; 1:e108. PMC: 3032298. DOI: 10.1038/cddis.2010.86. View

Hu Z, Wang J, Cheng G, Zhu X, Huang P, Yang D . Apogossypolone targets mitochondria and light enhances its anticancer activity by stimulating generation of singlet oxygen and reactive oxygen species. Chin J Cancer. 2011; 30(1):41-53. PMC: 4012262. DOI: 10.5732/cjc.010.10295. View

Malik S, Shen S, Marino G, BenYounes A, Maiuri M, Kroemer G . BH3 mimetics reveal the network properties of autophagy-regulatory signaling cascades. Autophagy. 2011; 7(8):914-6. DOI: 10.4161/auto.7.8.15785. View

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

Hwang J, Kuruvilla J, Mendelson D, Pishvaian M, Deeken J, Siu L . Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res. 2010; 16(15):4038-45. PMC: 3703245. DOI: 10.1158/1078-0432.CCR-10-0822. View

Martin A, Mitchell C, Rahmani M, Nephew K, Grant S, Dent P . Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther. 2009; 8(21):2084-96. PMC: 3887451. DOI: 10.4161/cbt.8.21.9895. View

Kazi A, Sun J, Doi K, Sung S, Takahashi Y, Yin H . The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem. 2010; 286(11):9382-92. PMC: 3059047. DOI: 10.1074/jbc.M110.203638. View

10.

Cragg M, Jansen E, Cook M, Harris C, Strasser A, Scott C . Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008; 118(11):3651-9. PMC: 2571034. DOI: 10.1172/JCI35437. View

11.

Mitchell C, Yacoub A, Hossein H, Martin A, Bareford M, Eulitt P . Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther. 2010; 10(9):903-17. PMC: 3040858. DOI: 10.4161/cbt.10.9.13273. View

12.

Lock R, Carol H, Houghton P, Morton C, Kolb E, Gorlick R . Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2007; 50(6):1181-9. DOI: 10.1002/pbc.21433. View

13.

Schimmer A, OBrien S, Kantarjian H, Brandwein J, Cheson B, Minden M . A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14(24):8295-301. DOI: 10.1158/1078-0432.CCR-08-0999. View

14.

Zheng C, Yang H, Zhang M, Lu S, Shi D, Wang J . Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity. Bioorg Med Chem Lett. 2011; 22(1):39-44. DOI: 10.1016/j.bmcl.2011.11.101. View

15.

Loberg R, McGregor N, Ying C, Sargent E, Pienta K . In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia. 2007; 9(12):1030-7. PMC: 2134900. DOI: 10.1593/neo.07778. View

16.

Bardwell P, Gu J, McCarthy D, Wallace C, Bryant S, Goess C . The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009; 182(12):7482-9. DOI: 10.4049/jimmunol.0802813. View

17.

Tagscherer K, Fassl A, Campos B, Farhadi M, Kraemer A, Bock B . Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008; 27(52):6646-56. DOI: 10.1038/onc.2008.259. View

18.

Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q . Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther. 2008; 7(7):2192-202. PMC: 2515935. DOI: 10.1158/1535-7163.MCT-08-0333. View

19.

Buron N, Porceddu M, Brabant M, Desgue D, Racoeur C, Lassalle M . Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One. 2010; 5(3):e9924. PMC: 2847598. DOI: 10.1371/journal.pone.0009924. View

20.

Zhai D, Jin C, Satterthwait A, Reed J . Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 2006; 13(8):1419-21. DOI: 10.1038/sj.cdd.4401937. View